New progress of bevacizumab in China!

On November 19, the official website of the State Food and Drug Administration showed that bevacizumab had made new progress, the original Roche had two new indications, and the biosimilar drug BAT1706 was approved for marketing

Screenshot from: NMPA

1.

Bevacizumab (Avastin) is a humanized monoclonal antibody IgG1, originally developed as Roche's Avastin, which is a vascular endothelial growth factor (VEGF) inhibitor

In February 2002, Roche's bevacizumab was approved by the US FDA, and then it was marketed in the European Union, Japan, China and other countries

In China, the approved indications for the drug include combined chemotherapy for metastatic colorectal cancer, first-line treatment of unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer, and recurrent glioblastoma Tumor, combined with atelizumab for the treatment of unresectable hepatocellular carcinoma that has not received systemic treatment in the past

2.

At present, Biotech has submitted a marketing authorization application for BAT1706 to China's NMPA, US FDA and European EMA, and has conducted international multi-center phase III clinical trials

On September 8 this year, Biotech announced that the company signed a licensing and commercialization agreement with Novartis subsidiary Sandoz, which will not cover bevacizumab injection BAT1706 in the United States, Europe, Canada and most other BAT1706 cooperations.

It is worth noting that recently Toyo Pharmaceuticals also submitted a marketing application for bevacizumab biosimilar (TAB008, trade name: Pu Xin Ting), and it has entered the "administrative approval" stage for the treatment of colorectal cancer and first-line Treatment of non-squamous cell non-small cell lung cancer

Reference source: Medicine Rubik's Cube, Medicine Guanlan